Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2-Reference-Cited by-同舟云学术

Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2

Published:2022-11 Issue:11 Volume:7 Page:2356-2363
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Devresse Arnaud,Sébastien Briol ,De Greef Julien,Lemaitre Florian,Boland Lidvine,Haufroid Vincent,Scohy Anais,Kabamba Benoit,Yombi Jean Cyr,Belkhir Leila,Darius Tom,Buemi Antoine,De Potter Kristell,Mantegazza Rebecca,Bearzatto Bertrand,Goffin Eric,Kanaan Nada

Publisher

Elsevier BV

Subject

Nephrology

Reference16 articles.

1. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2;Takashita;N Engl J Med,2022

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022

3. Special considerations for Paxlovid treatment among transplant recipients with SARS-CoV-2 infection;Fishbane;Am J Kidney Dis,2022

4. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT);Lemaitre;Therapie. Published online April 20,2022

5. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients;Salerno;Am J Transplant,2022

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series;Journal of Pharmaceutical Health Care and Sciences;2024-07-10

2. A biological pharmacology network to secure the risk of drug–drug interaction with nirmatrelvir/ritonavir;Therapies;2024-07

3. Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus;Frontiers in Pharmacology;2024-06-19

4. Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients;European Journal of Clinical Pharmacology;2024-05-01

5. Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study;BMC Nephrology;2024-04-08